Physician profile
John Carmichael Ricketts
NPI 1558780403
$4,912.36
in general payments reported to CMS, 2019-2025
13 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $306 · 2023: $2,241 · 2024: $1,756 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581 · Travel and Lodging: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.01 |
| Travel and Lodging | $1,924.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,019.96 | 2022-2025 | Mitraclip, Amplatzer Amulet |
| Heartflow, INC. | $393.73 | 2023-2025 | Ffrct |
| Edwards Lifesciences Corporation | $342.82 | 2022-2025 | Evoque, Pascal |
| Boston Scientific Corporation | $317.03 | 2022-2025 | Avvigo Guidance System, Watchman Access System, Watchman Flx |
| Biotronik INC. | $229.00 | 2022-2023 | Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $145.41 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $121.06 | 2022-2024 | Wainua |
| Novo Nordisk INC | $117.83 | 2021-2024 | Rybelsus, Ozempic |
| Cleerly, INC. | $107.05 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Atricure, INC. | $40.89 | 2023 | |
| Amgen INC. | $34.38 | 2024-2025 | Repatha, Repatha |
| Inspire Medical Systems, INC. | $26.75 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ricketts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.